对《miR-153抑制IDO1表达并增强CAR T细胞免疫疗法》的更正
Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
作者信息
Huang Qian, Xi Jiajia, Wang Lei, Wang Xu, Ma Xiaodong, Deng Qipan, Lu Yong, Kumar Munish, Zhou Zhiyuan, Li Ling, Zeng Zhaoyang, Young Ken H, Yi Qing, Zhang Mingzhi, Li Yong
机构信息
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, 510631, China.
出版信息
J Hematol Oncol. 2018 Jul 3;11(1):90. doi: 10.1186/s13045-018-0633-1.
Abstract
The original article [1] contains a spelling error in the authorship; the authors would like to note the correct spelling of the second author, Jiajia Xi.
摘要
原文章[1]在作者署名方面存在一处拼写错误；作者们特此说明第二作者Xi Jiajia（奚佳佳）的正确拼写。
相似文献
1
Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.对《miR-153抑制IDO1表达并增强CAR T细胞免疫疗法》的更正
J Hematol Oncol. 2018 Jul 3;11(1):90. doi: 10.1186/s13045-018-0633-1.
2
Correction to: miR-431 inhibits adipogenic differentiation of human bone marrow-derived mesenchymal stem cells via targeting insulin receptor substance 2.对《miR-431通过靶向胰岛素受体底物2抑制人骨髓间充质干细胞的成脂分化》的更正
Stem Cell Res Ther. 2019 Feb 21;10(1):62. doi: 10.1186/s13287-019-1173-5.
3
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.对《一项自体树突状细胞疫苗用于新诊断胶质母细胞瘤的大型3期临床试验的生存初步结果》的更正
J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.
4
Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.更正：新一代1928zT2嵌合抗原受体T细胞诱导急性淋巴细胞白血病髓外复发缓解。
J Hematol Oncol. 2019 Nov 20;12(1):117. doi: 10.1186/s13045-019-0816-4.
5
Correction to: Mass poisoning with NPS: 2C-E and Bromo-DragonFly.对《新型精神活性物质大规模中毒：2C-E和溴代蜻蜓》的勘误
Int J Legal Med. 2019 Jan;133(1):131. doi: 10.1007/s00414-018-1903-8.
6
Author Correction: Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.作者更正：在模拟人类癌症的模型中，BCL9/9l缺失可抑制Wnt驱动的肿瘤发生。
Nat Commun. 2019 Mar 26;10(1):1453. doi: 10.1038/s41467-019-09465-7.
7
Correction to: Collagen degradation as a possibility to determine the post-mortem interval (PMI) of animal bones: a validation study referring to an original study of Boaks et al. (2014).对以下内容的更正：胶原蛋白降解作为确定动物骨骼死后间隔时间（PMI）的一种可能性：一项参考Boaks等人（2014年）原始研究的验证研究。
Int J Legal Med. 2018 May;132(3):765. doi: 10.1007/s00414-018-1782-z.
8
Correction to: PAKs supplement improves immune status and body composition but not muscle strength in resistance trained individuals.对《PAKs补充剂可改善抗阻训练个体的免疫状态和身体成分，但不能增强肌肉力量》一文的更正
J Int Soc Sports Nutr. 2018 Nov 27;15(1):54. doi: 10.1186/s12970-018-0261-8.
9
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions.作者更正：大规模全转录组关联研究确定了新的前列腺癌风险区域。
Nat Commun. 2019 Jan 8;10(1):171. doi: 10.1038/s41467-018-08108-7.
10
The spurious dragonfly: the intricate nomenclatural problems regarding the names Libelloides and libelluloides (Neuroptera Ascalaphidae et Myrmeleontidae).伪蜻蜓：关于Libelloides和libelluloides（脉翅目：蝶角蛉科和蚁蛉科）名称的复杂命名问题。
Zootaxa. 2018 Feb 27;4387(3):524-540. doi: 10.11646/zootaxa.4387.3.7.
引用本文的文献
1
Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.嵌合抗原受体疗法在血液恶性肿瘤中的应用：抗原靶点及其临床研究进展。
Ann Hematol. 2020 Aug;99(8):1681-1699. doi: 10.1007/s00277-020-04020-7. Epub 2020 May 9.
2
MiR-153 reduces stem cell-like phenotype and tumor growth of lung adenocarcinoma by targeting Jagged1.miR-153 通过靶向 Jagged1 减少肺腺癌干细胞样表型和肿瘤生长。
Stem Cell Res Ther. 2020 May 6;11(1):170. doi: 10.1186/s13287-020-01679-7.
3
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.嵌合抗原受体T细胞疗法治疗结直肠癌
J Clin Med. 2020 Jan 9;9(1):182. doi: 10.3390/jcm9010182.
本文引用的文献
1
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.miR-153 抑制 IDO1 表达并增强 CAR T 细胞免疫疗法。
J Hematol Oncol. 2018 Apr 23;11(1):58. doi: 10.1186/s13045-018-0600-x.
Zotero 插件